AU2006283371A1 - Combinations comprising DMXAA for the treatment of cancer - Google Patents

Combinations comprising DMXAA for the treatment of cancer Download PDF

Info

Publication number
AU2006283371A1
AU2006283371A1 AU2006283371A AU2006283371A AU2006283371A1 AU 2006283371 A1 AU2006283371 A1 AU 2006283371A1 AU 2006283371 A AU2006283371 A AU 2006283371A AU 2006283371 A AU2006283371 A AU 2006283371A AU 2006283371 A1 AU2006283371 A1 AU 2006283371A1
Authority
AU
Australia
Prior art keywords
formula
compound
pharmaceutically acceptable
growth factor
prodrug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2006283371A
Other languages
English (en)
Inventor
Colin Green
Lloyd Kelland
Gail Rowlinson-Busza
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Antisoma Research Ltd
Original Assignee
Antisoma Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0517386A external-priority patent/GB0517386D0/en
Priority claimed from GB0604114A external-priority patent/GB0604114D0/en
Application filed by Antisoma Research Ltd filed Critical Antisoma Research Ltd
Publication of AU2006283371A1 publication Critical patent/AU2006283371A1/en
Assigned to ANTISOMA RESEARCH LIMITED reassignment ANTISOMA RESEARCH LIMITED Request for Assignment Assignors: ANTISOMA PLC
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
AU2006283371A 2005-08-26 2006-08-25 Combinations comprising DMXAA for the treatment of cancer Abandoned AU2006283371A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0517386A GB0517386D0 (en) 2005-08-26 2005-08-26 Combinations for the treatment of cancer
GB0517386.9 2005-08-26
GB0604114.9 2006-03-02
GB0604114A GB0604114D0 (en) 2006-03-02 2006-03-02 Combinations for the treatment of cancer
PCT/GB2006/003196 WO2007023302A1 (en) 2005-08-26 2006-08-25 Combinations comprising dmxaa for the treatment of cancer

Publications (1)

Publication Number Publication Date
AU2006283371A1 true AU2006283371A1 (en) 2007-03-01

Family

ID=37429252

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006283371A Abandoned AU2006283371A1 (en) 2005-08-26 2006-08-25 Combinations comprising DMXAA for the treatment of cancer

Country Status (14)

Country Link
US (1) US20100297112A1 (no)
EP (1) EP1917011A1 (no)
JP (1) JP2009506019A (no)
KR (1) KR20080047402A (no)
AU (1) AU2006283371A1 (no)
BR (1) BRPI0614965A2 (no)
CA (1) CA2620436A1 (no)
EC (1) ECSP088243A (no)
IL (1) IL189376A0 (no)
MA (1) MA29786B1 (no)
NO (1) NO20080649L (no)
RU (1) RU2404764C2 (no)
TN (1) TNSN08056A1 (no)
WO (1) WO2007023302A1 (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002009700A1 (en) 2000-07-28 2002-02-07 Cancer Research Technology Limited Cancer treatment by combination therapy
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
GB2386836B (en) 2002-03-22 2006-07-26 Cancer Res Ventures Ltd Anti-cancer combinations
GB2394658A (en) 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
JP2011506455A (ja) * 2007-12-13 2011-03-03 ノバルティス アーゲー 癌を処置するための治療薬の組み合わせ剤
KR102216772B1 (ko) * 2018-05-18 2021-02-17 주식회사 종근당 혈관차단제 및 탁산 화합물을 포함하는 암 예방 또는 치료용 조성물

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3655470A (en) * 1969-03-29 1972-04-11 Toa Gosei Chem Ind Process for the production of a foamed thermoplastic resin sheet
FR2516922A1 (fr) * 1981-11-25 1983-05-27 Lipha Acides (oxo-4-4h-(1)-benzopyran-8-yl) alcanoiques, sels et derives, preparation et medicament les contenant
DE3587500T2 (de) * 1984-12-04 1993-12-16 Lilly Co Eli Tumorbehandlung bei Säugetieren.
US4704355A (en) * 1985-03-27 1987-11-03 New Horizons Diagnostics Corporation Assay utilizing ATP encapsulated within liposome particles
US5281620A (en) * 1986-12-23 1994-01-25 Cancer Research Campaign Technology Limited Compounds having antitumor and antibacterial properties
US5126129A (en) * 1988-05-23 1992-06-30 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Cancer therapy using interleukin-2 and flavone compounds
US5620875A (en) * 1995-02-17 1997-04-15 University Of Portland Transfer of taxol from yew tree cuttings into a culture medium over time
US5863904A (en) * 1995-09-26 1999-01-26 The University Of Michigan Methods for treating cancers and restenosis with P21
EP0961617A4 (en) * 1996-12-13 2002-08-07 Lilly Co Eli LEUKOTRINE ANTAGONISTS FOR TREATING FOCAL BRAIN CHEMISTRY
HUP9904672A2 (hu) * 1997-03-21 2000-05-28 Eli Lilly And Co. Szájüregi laphámrák ellen alkalmazható leukotrién antagonisták
US6174873B1 (en) * 1998-11-04 2001-01-16 Supergen, Inc. Oral administration of adenosine analogs
DK1033364T3 (da) * 1999-03-01 2005-06-06 Pfizer Prod Inc Cyanholdige oxamidsyrer og -derivater som thyroideareceptorligander
DE60027719T2 (de) * 1999-06-14 2007-04-26 Cancer Research Technology Ltd. Krebstherapie
US6806257B1 (en) * 1999-10-20 2004-10-19 Board Of Trustees Of Southern Illinois University Flavones as inducible nitric oxide synthase inhibitors, cyclooxygenase-2 inhibitors and potassium channel activators
EP1259237A4 (en) * 2000-02-17 2004-07-28 Merck & Co Inc TREATMENT OR PREVENTION OF PROSTATE CANCER USING A SELECTIVE COX-2 INHIBITOR MEDICINE
JP2001247459A (ja) * 2000-03-03 2001-09-11 Oakland Uniservices Ltd 癌の組み合わせ療法
WO2002009700A1 (en) * 2000-07-28 2002-02-07 Cancer Research Technology Limited Cancer treatment by combination therapy
GB0121285D0 (en) * 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
GB2386836B (en) * 2002-03-22 2006-07-26 Cancer Res Ventures Ltd Anti-cancer combinations
GB2394658A (en) * 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
CA2523260A1 (en) * 2003-04-21 2004-11-04 Archemix Corporation Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
GB0321999D0 (en) * 2003-09-19 2003-10-22 Cancer Rec Tech Ltd Anti-cancer combinations

Also Published As

Publication number Publication date
TNSN08056A1 (en) 2009-07-14
RU2404764C2 (ru) 2010-11-27
IL189376A0 (en) 2008-06-05
EP1917011A1 (en) 2008-05-07
JP2009506019A (ja) 2009-02-12
ECSP088243A (es) 2008-08-29
CA2620436A1 (en) 2007-03-01
BRPI0614965A2 (pt) 2016-09-13
KR20080047402A (ko) 2008-05-28
MA29786B1 (fr) 2008-09-01
NO20080649L (no) 2008-05-26
US20100297112A1 (en) 2010-11-25
RU2008111492A (ru) 2009-10-10
WO2007023302A1 (en) 2007-03-01

Similar Documents

Publication Publication Date Title
ES2390237T3 (es) Combinaciones que comprenden un inhibidor de cdk y un anticuerpo anti-factor de crecimiento o un agente antimitótico
US20040034026A1 (en) Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity
US20090209496A1 (en) Methods and compositions for enhancing the efficacy of rtk inhibitors
CA2368369A1 (en) Docetaxel in combination with rhumab her2 for the treatment of cancers
AU2006283371A1 (en) Combinations comprising DMXAA for the treatment of cancer
KR102033305B1 (ko) 아스피린 및 다중 키나아제 억제제를 포함하는 항암제 내성 치료용 조성물
RU2404765C2 (ru) Комбинации (составы), включающие dmxaa для лечения рака
JP2009536956A (ja) 抗癌治療法
CN112236147A (zh) 包含双氟烷基-1,4-苯并二氮杂*酮化合物的组合物和其使用方法
AU2005265155A1 (en) Cancer chemotherapy
KR20210005714A (ko) 비스플루오로알킬-1,4-벤조디아제피논 화합물을 포함하는 조합 조성물 및 이의 사용 방법
JP2007511509A (ja) Ｅｔ−７４３およびパクリタキセルの使用を含むガンの併用療法
Pili et al. An open-label study to determine the maximum tolerated dose of the multitargeted tyrosine kinase inhibitor CEP-11981 in patients with advanced cancer
KR20070089158A (ko) 암의 치료를 위한ｎ-(3-메톡시-5-메틸피라진-2-일)-2-(4-[1,3,4-옥사디아졸-2-일]페닐)피리딘-3-설폰아미드 및 항-유사분열제의 조합물
CN108187055B (zh) 一种具有协同增效作用的抗癌组合物
TW202304427A (zh) 多激酶抑制劑的藥物組合物及其用途
JP7311177B2 (ja) Ａ－ＮＯＲ－５αアンドロスタン薬物と抗がん薬物との併用
JP2011513429A (ja) 改善された抗癌治療法
WO2014029016A1 (en) Compositions comprising a glycylcycline and a tyrosine kinase inhibitor for treating cancer
CN101309681A (zh) 用于治疗癌症的含有dmxaa的组合
RU2774721C2 (ru) Применение комбинированного лечения на основе антитела к PD-1 и апатиниба для лечения трижды негативного рака молочной железы
WO2019230679A1 (ja) 抗腫瘍剤及び腫瘍治療方法
MX2008010096A (es) Composiciones que comprenden un inhibidor de cinasa dependiente de la ciclina y un anticuerpo o antimicotico del factor de crecimiento
Robertson Antivascular Agents

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: ANTISOMA RESEARCH LIMITED

Free format text: FORMER APPLICANT(S): ANTISOMA PLC

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application